Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Defence Therapeutics (DTC) AI Stock Analysis

DE:DTC

Defence Therapeutics

(Frankfurt:DTC)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Accum platform and therapeutic pipelineThe Accumâ„¢ platform gives Defence Therapeutics a defined technological focus across immune-oncology and infectious-disease applications. If its delivery approach translates into better immune activation or treatment efficacy, it could support multiple programs and create a reusable foundation for longer-term pipeline development.
Negative Factors
No commercial revenueThe absence of revenue confirms that Defence Therapeutics remains dependent on development progress rather than an established commercial business. Without product sales, the company has no recurring operating inflow to fund research, making future financial performance highly dependent on successful commercialization.

Defence Therapeutics (DTC) vs. iShares MSCI Germany ETF (EWG)

-60%-40%-20%0%20%40%DE:DTC-50.22%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 19.70M
Dividend Yield
―
Average Volume (3M)
20.67K
Price to Earnings (P/E)
-3.2
Beta (1Y)
0.49
Revenue Growth
―
EPS Growth
-46.06%
Country
Germany
Employees
5
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Defence Therapeutics Business Overview & Revenue Model

Company Description

Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its ap...

Defence Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:DTC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:MDNATSE:MDNA43NeutralCAD 35.32M-2.06-360.29%――-33.27%
TSE:BCTTSE:BCT39UnderperformCAD 37.55M-0.33-170.70%――87.90%
TSE:BIOVTSE:BIOV29UnderperformCAD 2.04M-0.9169.89%―――

* Healthcare Sector Average

Performance Comparison

-75%-50%-25%0%25%DE:DTCTSE:MDNATSE:BCTTSE:BIOVTSE:ONCODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:DTC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:DTCDefence Therapeutics Inc0.23-0.30-56.60%
TSE:MDNAMedicenna Therapeutics0.46-1.04-69.67%
TSE:BCTBriaCell Therapeutics4.30-9.65-69.18%
TSE:BIOVBiovaxys Technology Corp0.07-0.19-73.08%
TSE:ONCOOnco-Innovations Ltd.1.470.000.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.